Q&A session in relation to new guidance material ‘Demonstrating the quality of listed probiotic medicines’

Background

This is a Q&A Session for Industry about the recently published guidance on listed probiotic medicines. This session is designed primarily for industry and regulatory affairs consultants who deal with listed complementary medicines.

The legislative requirements for listed probiotics medicines are complex. As such, we have developed this guidance to assist sponsors with making sense of the requirements and support compliance. Now that this guidance has been published, we would like to give industry the opportunity to ask questions and discuss any particular issues or clarifications they would like addressed.

Speaker

• Dr Jenny Cheng, Director, Complementary and OTC Medicines Branch, TGA

Slides